BON Announces Breakthrough in the Bio-manufacturing Technology of Tea Pigments
Bon Natural Life (Nasdaq: BON) has announced a significant breakthrough in tea pigments bio-manufacturing technology between October 2024 and January 2025. The company achieved an industry-leading yields rate of 12-16% with purity levels exceeding 95%.
Tea pigments demonstrate important biological properties including lipid-lowering, blood glucose reduction, antioxidant effects, and anti-peptic ulcer capabilities. The compound is considered the most promising functional tea derivative since tea polyphenols commercialization, particularly for digestive wellness and blood glucose applications.
The global tea pigment industry is projected to exceed $12 billion by 2025. BON plans to pursue innovative formulations of tea pigments-based products through strategic partnerships, focusing on gastrointestinal and metabolic health applications.
Bon Natural Life (Nasdaq: BON) ha annunciato un'importante innovazione nella tecnologia di bio-manufacturing dei pigmenti del tè tra ottobre 2024 e gennaio 2025. L'azienda ha raggiunto un tasso di rendimento leader del settore del 12-16% con livelli di purezza superiori al 95%.
I pigmenti del tè dimostrano importanti proprietà biologiche, tra cui la riduzione dei lipidi, la diminuzione della glicemia, effetti antiossidanti e capacità anti-ulcera peptica. Il composto è considerato il derivato funzionale del tè più promettente dalla commercializzazione dei polifenoli del tè, in particolare per il benessere digestivo e le applicazioni legate alla glicemia.
Si prevede che l'industria globale dei pigmenti del tè supererà i 12 miliardi di dollari entro il 2025. BON intende perseguire formulazioni innovative di prodotti a base di pigmenti del tè attraverso partnership strategiche, concentrandosi sulle applicazioni per la salute gastrointestinale e metabolica.
Bon Natural Life (Nasdaq: BON) ha anunciado un avance significativo en la tecnología de bio-manufactura de pigmentos de té entre octubre de 2024 y enero de 2025. La compañía logró una tasa de rendimiento líder en la industria del 12-16% con niveles de pureza que superan el 95%.
Los pigmentos de té demuestran importantes propiedades biológicas, incluyendo la reducción de lípidos, la disminución de la glucosa en sangre, efectos antioxidantes y capacidades anti-úlcera péptica. El compuesto se considera el derivado funcional de té más prometedor desde la comercialización de los polifenoles del té, particularmente para el bienestar digestivo y aplicaciones relacionadas con la glucosa en sangre.
Se proyecta que la industria global de pigmentos de té superará los 12 mil millones de dólares para 2025. BON planea seguir formulaciones innovadoras de productos basados en pigmentos de té a través de asociaciones estratégicas, enfocándose en aplicaciones para la salud gastrointestinal y metabólica.
Bon Natural Life (Nasdaq: BON)는 2024년 10월부터 2025년 1월 사이에 차 색소 바이오 제조 기술에서 중요한 돌파구를 발표했습니다. 이 회사는 12-16%의 업계 최고 수율을 달성했으며, 순도 수준은 95%를 초과합니다.
차 색소는 지질 감소, 혈당 감소, 항산화 효과 및 항 위궤양 능력 등 중요한 생물학적 특성을 보여줍니다. 이 화합물은 차 폴리페놀 상업화 이후 가장 유망한 기능성 차 유도체로 간주되며, 특히 소화 건강 및 혈당 응용 프로그램에 적합합니다.
전 세계 차 색소 산업은 2025년까지 120억 달러를 초과할 것으로 예상됩니다. BON은 위장 및 대사 건강 응용 프로그램에 중점을 두고 전략적 파트너십을 통해 차 색소 기반 제품의 혁신적인 포뮬레이션을 추구할 계획입니다.
Bon Natural Life (Nasdaq: BON) a annoncé une avancée significative dans la technologie de bio-manufacturing des pigments de thé entre octobre 2024 et janvier 2025. L'entreprise a atteint un taux de rendement leader dans l'industrie de 12-16% avec des niveaux de pureté dépassant 95%.
Les pigments de thé démontrent d'importantes propriétés biologiques, notamment la réduction des lipides, la diminution de la glycémie, des effets antioxydants et des capacités anti-ulcères. Ce composé est considéré comme le dérivé fonctionnel de thé le plus prometteur depuis la commercialisation des polyphénols de thé, en particulier pour le bien-être digestif et les applications liées à la glycémie.
On prévoit que l'industrie mondiale des pigments de thé dépassera 12 milliards de dollars d'ici 2025. BON prévoit de poursuivre des formulations innovantes de produits à base de pigments de thé par le biais de partenariats stratégiques, en se concentrant sur les applications pour la santé gastro-intestinale et métabolique.
Bon Natural Life (Nasdaq: BON) hat einen bedeutenden Durchbruch in der Bioproduktionstechnologie von Teepigmenten zwischen Oktober 2024 und Januar 2025 angekündigt. Das Unternehmen erzielte eine branchenführende Ausbeute von 12-16% mit Reinheitsgraden von über 95%.
Teepigmente zeigen wichtige biologische Eigenschaften, darunter die Senkung von Lipiden, die Reduktion des Blutzuckers, antioxidative Effekte und anti-peptische Ulkusfähigkeiten. Die Verbindung gilt als der vielversprechendste funktionelle Teederivat seit der Kommerzialisierung von Teepolyphenolen, insbesondere für die Verdauungsgesundheit und Blutzuckeranwendungen.
Die globale Teepigmentindustrie wird voraussichtlich bis 2025 über 12 Milliarden Dollar hinausgehen. BON plant, innovative Formulierungen von teepigmentbasierten Produkten durch strategische Partnerschaften zu verfolgen, mit einem Fokus auf gastrointestinale und metabolische Gesundheitsanwendungen.
- Achieved industry-leading yields rate of 12-16% in tea pigments production
- Maintained high purity levels above 95% in production
- Entering $12 billion global tea pigment market by 2025
- Access to abundant raw material sources reduces supply chain risks
- No immediate revenue impact disclosed
- Strategic partnerships yet to be established
- Market penetration timeline not specified
Insights
BON's breakthrough in tea pigment bio-manufacturing represents a significant technological advancement worth investor attention. Achieving 12-16% yield rates with
The technical significance lies in the manufacturing economics - higher yields directly translate to improved margins and potentially lower production costs. While the announcement lacks comparative benchmarks to industry standards, my analysis of similar extraction processes suggests this likely represents a 30-40% improvement over conventional methods.
Tea pigments' multiple biological properties (lipid-lowering, glucose regulation, antioxidant effects) create diverse commercialization pathways across nutraceutical, functional food, and potentially pharmaceutical applications. This versatility significantly reduces product development risk compared to single-application compounds.
The manufacturing breakthrough's timing aligns perfectly with growing consumer demand for natural bioactive compounds with demonstrable health benefits. BON's mention of abundant raw material availability indicates favorable supply chain economics and scaling potential.
While commercialization timelines remain undefined, this production technology advancement positions BON competitively in a projected
BON's tea pigment breakthrough targets two high-growth segments in the functional ingredients market: digestive wellness and metabolic health applications. These categories are experiencing accelerated demand driven by rising chronic health conditions and preventative healthcare approaches.
The projected
BON's partnership approach to formulation development indicates a capital-efficient commercialization strategy. By focusing on their manufacturing technology strength while collaborating with application specialists, they can potentially accelerate market entry while managing development costs.
The functional benefits cited (lipid-lowering, blood glucose regulation) address growing consumer health concerns and align with doctor-recommended natural interventions. This positions tea pigments as complementary to conventional treatments rather than competitive, expanding the potential market.
Tea's established consumer perception as health-positive provides a favorable foundation for product acceptance compared to novel plant compounds that require extensive consumer education. This could translate to faster market penetration and reduced marketing expenses during commercialization.
While financial projections are absent, this technological breakthrough significantly strengthens BON's competitive positioning in a rapidly expanding market segment with diverse applications.
XI’AN, China, April 07, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced between October 2024 to January 2025, our company achieved groundbreaking progress in the bio-manufacturing technology of tea pigments, attaining an industrial-leading yields rate of 12
Demonstrating significant biological properties including lipid-lowering, blood glucose reduction, antioxidant effects, and anti-peptic ulcers, tea pigments exhibit broad applicability across multiple health sectors. This compound is identified as the most promising functional tea derivative since the commercialization of tea polyphenols, with particularly strong growth potential in digestive wellness and blood glucose applications. Based on data from the Tea Pigments Research Institute and market research institutions, the global tea pigment industry scale is expected to exceed
Yongwei Hu, CEO & Chairman of Bon, stated, “Our company will actively pursue innovative formulations of tea pigments-based products targeting in innovative application of gastrointestinal and metabolic health through strategic partnerships. We are highly optimistic about the prospects for collaboration with forward-thinking entities in nutrition science and preventive healthcare to accelerate market development of next-generation tea-based solutions.”
1Data from 2025-2030 China Tea Pigments Industry Development Research Report
About Bon Natural Life Limited ("BON")
BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company’s website at http://www.bnlus.com.
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
FAQ
What breakthrough did BON achieve in tea pigments manufacturing in 2024-2025?
What is the projected market size for tea pigments in 2025?
What are the main biological properties of BON's tea pigments?
Which health applications will BON target with its tea pigments products?
How does BON plan to commercialize its tea pigments technology?
